Xiao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiao Li has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Juzheng Yuan
Department of General Surgery, Xijing Hospital, Air Force Medical University, Xi’an, China
8 shared publicationsXudan Wang
Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China
5 shared publicationsFuyuan Liu
Department of General Surgery, Xijing Hospital, Air Force Medical University, Xi’an, China
4 shared publications- Shuqiang Yue
Department of General Surgery, Xijing Hospital, Air Force Medical University, Xi’an, China
4 shared publications Weikang Wu
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
4 shared publicationsWeiwei Cao
Department of Clinical Laboratory, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China
4 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1124
PPARγ suppresses the tumorigenesis of retroperitoneal liposarcoma via inactivation of the PI3K/AKT signaling pathway
- 30 July 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1124
Open AccessPPARγ suppresses the tumorigenesis of retroperitoneal liposarcoma via inactivation of the PI3K/AKT signaling pathway
- Open Access
- 13 September 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e948952
Giant Intra-Abdominal Tumor, Compatible with Liposarcoma: A Case Report and Literature Review
BACKGROUND We report a case of a giant (55×35×27 cm, 26 kg) retroperitoneal liposarcoma (RPLS) to provide surgical insights for managing such complex tumors. Due to the potential space in the retroperitoneal cavity, primary retroperitoneal liposarcoma can grow to very large sizes without causing typical symptoms, frequently encasing critical vessels and organs and making resection highly challenging. Most chemotherapy drugs have limited effectiveness against RPLS, while radiotherapy dosages are significantly constrained by toxicity concerns. These limitations underscore why complete surgical resection (R0) continues to be the cornerstone of RPLS treatment and the single most important prognostic factor. While R0 resection remains the primary treatment, innovative approaches are needed to improve outcomes. CASE REPORT A 59-year-old man came for medical treatment due to the continuous growth of an abdominal mass for 2 years. Imaging revealed tumor encasement of the left renal vessels and descending colon, with compression of the aorta and inferior vena cava. Following multidisciplinary evaluation, vascular-oriented resection (VOR) combined with total retroperitoneal lipectomy (TRL) was performed, achieving complete tumor removal along with the involved left kidney and partial colon. Pathology confirmed dedifferentiated liposarcoma (MDM2/CDK4+, Ki-67 10-30%). Postoperatively, the patient showed significant improvement, with resolved lower-limb edema and dyspnea. CONCLUSIONS This case demonstrates the feasibility of VOR combined with TRL for giant retroperitoneal liposarcoma, highlighting the importance of preoperative 3D vascular reconstruction and multidisciplinary collaboration. Although surgical techniques have advanced, the 5-year recurrence rate remains unacceptably high at nearly 50%, highlighting the urgent need to explore more effective adjuvant therapies.
- 13 September 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e948952
Open AccessGiant Intra-Abdominal Tumor, Compatible with Liposarcoma: A Case Report and Literature Review
BACKGROUND We report a case of a giant (55×35×27 cm, 26 kg) retroperitoneal liposarcoma (RPLS) to provide surgical insights for managing such complex tumors. Due to the potential space in the retroperitoneal cavity, primary retroperitoneal liposarcoma can grow to very large sizes without causing typical symptoms, frequently encasing critical vessels and organs and making resection highly challenging. Most chemotherapy drugs have limited effectiveness against RPLS, while radiotherapy dosages are significantly constrained by toxicity concerns. These limitations underscore why complete surgical resection (R0) continues to be the cornerstone of RPLS treatment and the single most important prognostic factor. While R0 resection remains the primary treatment, innovative approaches are needed to improve outcomes. CASE REPORT A 59-year-old man came for medical treatment due to the continuous growth of an abdominal mass for 2 years. Imaging revealed tumor encasement of the left renal vessels and descending colon, with compression of the aorta and inferior vena cava. Following multidisciplinary evaluation, vascular-oriented resection (VOR) combined with total retroperitoneal lipectomy (TRL) was performed, achieving complete tumor removal along with the involved left kidney and partial colon. Pathology confirmed dedifferentiated liposarcoma (MDM2/CDK4+, Ki-67 10-30%). Postoperatively, the patient showed significant improvement, with resolved lower-limb edema and dyspnea. CONCLUSIONS This case demonstrates the feasibility of VOR combined with TRL for giant retroperitoneal liposarcoma, highlighting the importance of preoperative 3D vascular reconstruction and multidisciplinary collaboration. Although surgical techniques have advanced, the 5-year recurrence rate remains unacceptably high at nearly 50%, highlighting the urgent need to explore more effective adjuvant therapies.
- Top Cited PapersOpen Access
- 8 May 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (4) , 931-945
Decoding the resistin-CAP1 pathway in intermediate monocytes mediating liver allograft rejection
- 8 May 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 83 (4) , 931-945
Top Cited PapersOpen AccessDecoding the resistin-CAP1 pathway in intermediate monocytes mediating liver allograft rejection
- 5 July 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (7) , 167336
EREG silencing inhibits tumorigenesis via inactivating ERK/p38 MAPK pathway in pancreatic ductal adenocarcinoma
- 5 July 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1870 (7) , 167336
EREG silencing inhibits tumorigenesis via inactivating ERK/p38 MAPK pathway in pancreatic ductal adenocarcinoma
- 18 March 2024
- Published by Elsevier in Transplantation Reviews
- Vol. 38 (2) , 100841
Research progress on anatomy reconstruction of rat orthotopic liver transplantation
- 18 March 2024
- Published by Elsevier in Transplantation Reviews
- Vol. 38 (2) , 100841
Research progress on anatomy reconstruction of rat orthotopic liver transplantation
- Open Access
- 13 December 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1174999
Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery
Objective: To assess the efficacy and safety of camrelizumab plus different targeted drugs in adjuvant therapy after hepatocellular carcinoma (HCC) surgery.Patients and methods: This retrospective cohort study included HCC patients who, after undergoing failed postoperative adjuvant lenvatinib therapy, received intravenous camrelizumab 200 mg every 3 weeks (C group, n = 97), camrelizumab plus oral apatinib 250 mg daily (C+A group, n = 125), camrelizumab plus oral lenvatinib 12 mg daily (for bodyweight ≥60 kg)/lenvatinib 8 mg daily (for bodyweight n = 120), or camrelizumab plus oral sorafenib 400 mg bi-daily (C+S group, n = 114) between October 2020 and October 2021. The outcomes including the objective response rate (ORR) and disease control rate (DCR) were evaluated by RECIST 1.1 and iRECIST. The median progression-free survival (mPFS), median overall survival (mOS), 6-month OS rate, 12-month OS rate, and adverse events were evaluated.Results: As of 31 May 2022 with last follow-up time, the ORR was 17.2% for the C group, 44.6% for the C+A group, 47.9% for the C+L group, and 36.3% for the C+S group. The DCR was 72.0% for the C group, 81.8% for the C+A group, 85.5% for the C+L group, and 77.9% for the C+S group. The mPFS was 11.0 months (10.1–12.8) for the C group, 14.0 months (12.7–16.5) for the C+A group, 18.0 months (16.9–20.1) for the C+L group, and 12.0 months (9.7–14.4) for the C+S group. The mOS was 13.0 months (11.6–15.3) for the C group, 17.0 months (15.8–19.4) for the C+A group, 19.0 months (17.7–20.2) for the C+L group, and 15.0 months (14.1–17.3) for the C+S group. Grade 3 or 4 treatment-related adverse events occurred in 14 patients (14.4%) for the C group, 10 patients (8.0%) for the C+A group, 5 patients (4.2%) for the C+L group, and 11 patients (9.6%) for the C+S group. The most common adverse events were fatigue and transaminitis.Conclusion: Camrelizumab combined with lenvatinib as adjuvant therapy showed promising efficacy and manageable safety in HCC patients. It might be a potential adjuvant therapy or second-line treatment for these patients.
- 13 December 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1174999
Open AccessClinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery
Objective: To assess the efficacy and safety of camrelizumab plus different targeted drugs in adjuvant therapy after hepatocellular carcinoma (HCC) surgery.Patients and methods: This retrospective cohort study included HCC patients who, after undergoing failed postoperative adjuvant lenvatinib therapy, received intravenous camrelizumab 200 mg every 3 weeks (C group, n = 97), camrelizumab plus oral apatinib 250 mg daily (C+A group, n = 125), camrelizumab plus oral lenvatinib 12 mg daily (for bodyweight ≥60 kg)/lenvatinib 8 mg daily (for bodyweight n = 120), or camrelizumab plus oral sorafenib 400 mg bi-daily (C+S group, n = 114) between October 2020 and October 2021. The outcomes including the objective response rate (ORR) and disease control rate (DCR) were evaluated by RECIST 1.1 and iRECIST. The median progression-free survival (mPFS), median overall survival (mOS), 6-month OS rate, 12-month OS rate, and adverse events were evaluated.Results: As of 31 May 2022 with last follow-up time, the ORR was 17.2% for the C group, 44.6% for the C+A group, 47.9% for the C+L group, and 36.3% for the C+S group. The DCR was 72.0% for the C group, 81.8% for the C+A group, 85.5% for the C+L group, and 77.9% for the C+S group. The mPFS was 11.0 months (10.1–12.8) for the C group, 14.0 months (12.7–16.5) for the C+A group, 18.0 months (16.9–20.1) for the C+L group, and 12.0 months (9.7–14.4) for the C+S group. The mOS was 13.0 months (11.6–15.3) for the C group, 17.0 months (15.8–19.4) for the C+A group, 19.0 months (17.7–20.2) for the C+L group, and 15.0 months (14.1–17.3) for the C+S group. Grade 3 or 4 treatment-related adverse events occurred in 14 patients (14.4%) for the C group, 10 patients (8.0%) for the C+A group, 5 patients (4.2%) for the C+L group, and 11 patients (9.6%) for the C+S group. The most common adverse events were fatigue and transaminitis.Conclusion: Camrelizumab combined with lenvatinib as adjuvant therapy showed promising efficacy and manageable safety in HCC patients. It might be a potential adjuvant therapy or second-line treatment for these patients.
- Open Access
- 5 August 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 924059
Construction and experimental verification of user-friendly molecular subtypes mediated by immune-associated genes in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) accounts for third most cancer death globally, and its prognosis continues to be poor even with many novel therapeutic approaches emerging. The advent of immunotherapy seems to offer new hope, but low response rates are an unresolved problem. To gain further knoeledge of the effect of immune-related genes in HCC, we examined the connection between immune-related genes and the immune microenvironment in HCC through the HCC transcriptome dataset. The study also aimed to construct and experimentally validate user-friendly molecular subtypes mediated by immune-related genes in HCC. The immune cell infiltration patterns differs in HCC adjacent non-disease tissues and cancerous tissues. Patients with HCC could be classified into 2 subtypes: subtype A and subtype B. Specifically, subtype A shows characteristics of a hot tumor, in which the infiltration of cells exhibiting antigens and the expression of other crucial factors associated with immune function are higher than in a cold tumor. In addition, we identified Hub genes for the different subtypes and constructed a prognostic prediction model based on six genes (KLRB1, KLF2, S100A9, MSC, ANXA5, and IMPDH1). Further experimental analysis of HCC samples exhibited that the expression levels of KLF2 and ANXA5 were associated with immune cell infiltration and expression of PD-L1 in cancer tissues. Our work suggests that the expression of immune-related genes has crucial effect on the tumor microenvironment and prognosis of HCC patients and may be associated with immunotherapeutic response, which provides new clues for the widespread and effective application of immunotherapy in HCC.
- 5 August 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 924059
Open AccessConstruction and experimental verification of user-friendly molecular subtypes mediated by immune-associated genes in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) accounts for third most cancer death globally, and its prognosis continues to be poor even with many novel therapeutic approaches emerging. The advent of immunotherapy seems to offer new hope, but low response rates are an unresolved problem. To gain further knoeledge of the effect of immune-related genes in HCC, we examined the connection between immune-related genes and the immune microenvironment in HCC through the HCC transcriptome dataset. The study also aimed to construct and experimentally validate user-friendly molecular subtypes mediated by immune-related genes in HCC. The immune cell infiltration patterns differs in HCC adjacent non-disease tissues and cancerous tissues. Patients with HCC could be classified into 2 subtypes: subtype A and subtype B. Specifically, subtype A shows characteristics of a hot tumor, in which the infiltration of cells exhibiting antigens and the expression of other crucial factors associated with immune function are higher than in a cold tumor. In addition, we identified Hub genes for the different subtypes and constructed a prognostic prediction model based on six genes (KLRB1, KLF2, S100A9, MSC, ANXA5, and IMPDH1). Further experimental analysis of HCC samples exhibited that the expression levels of KLF2 and ANXA5 were associated with immune cell infiltration and expression of PD-L1 in cancer tissues. Our work suggests that the expression of immune-related genes has crucial effect on the tumor microenvironment and prognosis of HCC patients and may be associated with immunotherapeutic response, which provides new clues for the widespread and effective application of immunotherapy in HCC.
- Open Access
- 13 July 2022
- Published by Taylor & Francis in All Life
- Vol. 15 (1) , 808-819
Identification of a costimulatory molecule-based signature to predict prognostic risk of pancreatic adenocarcinoma
We aimed to investigate the prognostic value of costimulatory molecules in PAAD by generating a CMS. Gene expression data and clinical factors of PAAD patients were obtained from TCGA. The signature was constructed using the survival package progressive Cox risk proportional regression model. Analyses of CMS-related genes, pathways, immune cell infiltration, and somatic mutations were conducted. A five-gene-based CMS was developed, and the risk score for CMS could be an independent risk factor for PAAD patients. Patients were divided into high- and low-risk groups based on the median Y of the CMS model. Differential analysis revealed 341 DEGs between the groups, and KEGG analysis demonstrated that these positively related genes in the high-risk group were mainly involved in chemical synaptic transmission pathway modulation and trans-synaptic signaling pathway regulation. Immune cell infiltration analysis revealed that the high-risk patients had higher proportions of M1 macrophages and T+ CD4 cells, but a lower proportion of M2 macrophages than that of the low-risk group. Mutational analysis revealed that the high-risk group showed a higher proportion of somatic mutations compared with that of the low-risk group. A CMS was developed, and the risk score could be an independent risk factor for PAAD patients.
- 13 July 2022
- Published by Taylor & Francis in All Life
- Vol. 15 (1) , 808-819
Open AccessIdentification of a costimulatory molecule-based signature to predict prognostic risk of pancreatic adenocarcinoma
We aimed to investigate the prognostic value of costimulatory molecules in PAAD by generating a CMS. Gene expression data and clinical factors of PAAD patients were obtained from TCGA. The signature was constructed using the survival package progressive Cox risk proportional regression model. Analyses of CMS-related genes, pathways, immune cell infiltration, and somatic mutations were conducted. A five-gene-based CMS was developed, and the risk score for CMS could be an independent risk factor for PAAD patients. Patients were divided into high- and low-risk groups based on the median Y of the CMS model. Differential analysis revealed 341 DEGs between the groups, and KEGG analysis demonstrated that these positively related genes in the high-risk group were mainly involved in chemical synaptic transmission pathway modulation and trans-synaptic signaling pathway regulation. Immune cell infiltration analysis revealed that the high-risk patients had higher proportions of M1 macrophages and T+ CD4 cells, but a lower proportion of M2 macrophages than that of the low-risk group. Mutational analysis revealed that the high-risk group showed a higher proportion of somatic mutations compared with that of the low-risk group. A CMS was developed, and the risk score could be an independent risk factor for PAAD patients.
- Open Access
- 10 December 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (2) , 9435-9451
Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma
ABSTRCT The α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) have certain diagnostic value, but their potential value in prognosis prediction, especially immunotherapy response prediction, remains unclear in liver cancer. Through the tumor-free survival (TFS) and overall survival (OS) rates analyses of serum AFP and sICAM-1 levels in 87 patients with primary hepatocellular carcinoma (HCC), the patients whose AFP and sICAM-1 levels were normal (AFP < 20 μg/L or sICAM-1 < 1000 μg/L) before surgery or recovered to normal after surgery exhibited a lower tumor recurrence rate and better OS than patients with elevated serum levels of the two markers. Combined analysis showed that patients with synchronously elevated levels of AFP and sICAM-1 showed the lowest TFS and OS. In addition, the RNA-seq data and clinical information of The Cancer Genome Atlas Liver Hepatocellular Carcinoma were collected to analyze the predictive values of AFP and ICAM-1 in the diagnosis, prognosis and immunotherapy of HCC. The results indicated that the combined application of the two indicators had higher accuracy in both the diagnosis and prognostic prediction of HCC by receiver operating characteristic curves. AFP and ICAM-1 were significantly correlated with multiple immune cells in HCC samples but not in normal samples. The patients with low expression of the two indicators were most likely to benefit from the immune checkpoint blockade therapy. In conclusion, AFP and ICAM-1 play vital roles in the diagnosis, prognostic prediction, and immunotherapy of HCC, suggesting that they are considered as prognostic predictors in clinical practice.
- 10 December 2021
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (2) , 9435-9451
Open AccessPotentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma
ABSTRCT The α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) have certain diagnostic value, but their potential value in prognosis prediction, especially immunotherapy response prediction, remains unclear in liver cancer. Through the tumor-free survival (TFS) and overall survival (OS) rates analyses of serum AFP and sICAM-1 levels in 87 patients with primary hepatocellular carcinoma (HCC), the patients whose AFP and sICAM-1 levels were normal (AFP < 20 μg/L or sICAM-1 < 1000 μg/L) before surgery or recovered to normal after surgery exhibited a lower tumor recurrence rate and better OS than patients with elevated serum levels of the two markers. Combined analysis showed that patients with synchronously elevated levels of AFP and sICAM-1 showed the lowest TFS and OS. In addition, the RNA-seq data and clinical information of The Cancer Genome Atlas Liver Hepatocellular Carcinoma were collected to analyze the predictive values of AFP and ICAM-1 in the diagnosis, prognosis and immunotherapy of HCC. The results indicated that the combined application of the two indicators had higher accuracy in both the diagnosis and prognostic prediction of HCC by receiver operating characteristic curves. AFP and ICAM-1 were significantly correlated with multiple immune cells in HCC samples but not in normal samples. The patients with low expression of the two indicators were most likely to benefit from the immune checkpoint blockade therapy. In conclusion, AFP and ICAM-1 play vital roles in the diagnosis, prognostic prediction, and immunotherapy of HCC, suggesting that they are considered as prognostic predictors in clinical practice.